Diagnostyka S.A.
Diagnostyka S.A. operates as a medical laboratory. The company was founded in 1998 and is headquartered in Kraków, Poland.
Diagnostyka S.A. (DIA) - Net Assets
Latest net assets as of : zł- PLN
Based on the latest financial reports, Diagnostyka S.A. (DIA) has net assets worth zł- PLN as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł-) and total liabilities (zł-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Diagnostyka S.A. - Net Assets Trend (None–None)
This chart illustrates how Diagnostyka S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Diagnostyka S.A. (None–None)
The table below shows the annual net assets of Diagnostyka S.A. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Diagnostyka S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Diagnostyka S.A. Competitors by Market Cap
The table below lists competitors of Diagnostyka S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vcanbio Cell & Gene Engineering Corp Ltd
SHG:600645
|
$1.38 Billion |
|
Foreign Trade Bank of Latin America Inc
NYSE:BLX
|
$1.38 Billion |
|
Polaris Bay Group Co Ltd
SHG:600155
|
$1.38 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
$1.38 Billion |
|
Hebei Hengshui Laobaigan Liquor Co Ltd
SHG:600559
|
$1.38 Billion |
|
Tabcorp Holdings Ltd
AU:TAH
|
$1.38 Billion |
|
Lucid Group Inc
NASDAQ:LCID
|
$1.38 Billion |
|
BBMG Corp Class A
SHG:601992
|
$1.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diagnostyka S.A.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Diagnostyka S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Diagnostyka S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Diagnostyka S.A.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $83,980,968
- Average return on equity (ROE) among peers: 11.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diagnostyka S.A. (DIA) | zł- | N/A | N/A | $1.38 Billion |
| Biomaxima (BMX) | $25.94 Million | 30.64% | 1.06x | $7.70 Million |
| Scope Fluidics SA (SCP) | $16.88 Million | -24.72% | 0.11x | $52.93 Million |
| Selvita S.A. (SLV) | $49.19 Million | 21.34% | 0.48x | $129.09 Million |
| Voxel S.A. (VOX) | $243.91 Million | 18.21% | 0.92x | $144.21 Million |